Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept versus calcineurin inhibitor conversion for cardiovascular risk in kidney transplant recipients
NL-OMON45007Phase 4Active, not recruiting
- Sponsor
- Akademiska sjukhuset
- Start
- Jul 2015
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of belatacept, tacrolimus and cyclosporine in kidney transplant immunosuppression (2 arms), sponsored by Akademiska sjukhuset. Primary endpoint: Estimated risk of major adverse cardiovascular events. Started Jul 2015; status: active, not recruiting.
02
Drugs
belatacepttacrolimuscyclosporine
03
Conditions
kidney transplant immunosuppression
Beyond the preview
Go deeper on NL-OMON45007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45007.